Nantkwest Stock Price, News & Analysis (NASDAQ:NK)

$5.07 0.33 (6.96 %)
(As of 12/17/2017 12:45 PM ET)
Previous Close$5.07
Today's Range$4.73 - $5.10
52-Week Range$2.71 - $8.45
Volume538,701 shs
Average Volume236,214 shs
Market Capitalization$402.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Nantkwest (NASDAQ:NK)

Nantkwest logoNantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NK
CUSIPN/A
Phone+1-858-6330300

Debt

Debt-to-Equity Ratio0.01%
Current Ratio5.47%
Quick Ratio5.47%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales10,071.56
Cash FlowN/A
Price / CashN/A
Book Value$3.56 per share
Price / Book1.42

Profitability

Trailing EPS($1.18)
Net Income$-120,800,000.00
Net Margins-204,606.36%
Return on Equity-36.21%
Return on Assets-32.04%

Miscellaneous

Employees82
Outstanding Shares79,460,000

Nantkwest (NASDAQ:NK) Frequently Asked Questions

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) posted its earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. Nantkwest had a negative net margin of 204,606.36% and a negative return on equity of 36.21%. View Nantkwest's Earnings History.

Where is Nantkwest's stock going? Where will Nantkwest's stock price be in 2017?

4 equities research analysts have issued 1 year price objectives for Nantkwest's stock. Their predictions range from $3.00 to $9.00. On average, they anticipate Nantkwest's share price to reach $5.33 in the next year. View Analyst Ratings for Nantkwest.

What are Wall Street analysts saying about Nantkwest stock?

Here are some recent quotes from research analysts about Nantkwest stock:

  • 1. According to Zacks Investment Research, "NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. " (11/14/2017)
  • 2. Jefferies Group LLC analysts commented, "Following recent development updates, we have adjusted our model to reflect increased risks, delayed timelines and reprioritization of certain programs. We view NK shares as fairly valued and see no meaningful catalysts for NK over the next 12-18 month period. We downgrade to Hold with a new PT of $6." (1/24/2017)

Who are some of Nantkwest's key competitors?

Who are Nantkwest's key executives?

Nantkwest's management team includes the folowing people:

  • Patrick Soon-Shiong M.D., Chairman of the Board, Chief Executive Officer (Age 64)
  • Barry J. Simon M.D., President, Chief Operating Officer, Director (Age 52)
  • Steven Gorlin, Vice Chairman of the Board (Age 79)
  • Richard J. Tajak, Interim Chief Financial Officer (Age 64)
  • Sonja Nelson, Chief Accounting Officer (Age 44)
  • Michael D. Blaszyk, Independent Director (Age 64)
  • Frederick W. Driscoll, Independent Director (Age 66)
  • John T. Potts Jr. M.D., Independent Director (Age 85)
  • John C. Thomas Jr., Independent Director (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Who owns Nantkwest stock?

Nantkwest's stock is owned by many different of institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.06%), JPMorgan Chase & Co. (0.03%) and Russell Investments Group Ltd. (0.03%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.

Who bought Nantkwest stock? Who is buying Nantkwest stock?

Nantkwest's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., SG Americas Securities LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Nantkwest.

How do I buy Nantkwest stock?

Shares of Nantkwest can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nantkwest's stock price today?

One share of Nantkwest stock can currently be purchased for approximately $5.07.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $402.84 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-120,800,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Nantkwest employs 82 workers across the globe.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 John Hopkins Ct, SAN DIEGO, CA 92121-1121, United States. The biotechnology company can be reached via phone at +1-858-6330300 or via email at [email protected]


MarketBeat Community Rating for Nantkwest (NK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nantkwest (NASDAQ:NK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.33
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.40$11.40$11.40$11.40
Price Target Upside: 130.30% upside93.88% upside93.88% upside147.83% upside

Nantkwest (NASDAQ:NK) Consensus Price Target History

Price Target History for Nantkwest (NASDAQ:NK)

Nantkwest (NASDAQ:NK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Raymond James FinancialReiterated RatingHoldMediumView Rating Details
8/14/2017CitigroupSet Price TargetSell$3.00LowView Rating Details
5/8/2017Jefferies GroupSet Price TargetHold$4.00MediumView Rating Details
3/17/2017FBR & CoReiterated RatingOutperform -> Outperform$22.00 -> $9.00LowView Rating Details
8/19/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
8/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$32.00 -> $23.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Nantkwest (NASDAQ:NK) Earnings History and Estimates Chart

Earnings by Quarter for Nantkwest (NASDAQ:NK)

Nantkwest (NASDAQ NK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q2($0.35)($0.41)$0.10 million$0.01 millionViewN/AView Earnings Details
5/16/2016Q1($0.24)($0.38)$0.10 million$0.01 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Nantkwest (NASDAQ:NK) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.24 EPS
Next Year EPS Consensus Estimate: $-1.7 EPS

Dividends

Dividend History for Nantkwest (NASDAQ:NK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nantkwest (NASDAQ NK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 70.19%
Institutional Ownership Percentage: 19.14%
Insider Trades by Quarter for Nantkwest (NASDAQ:NK)
Institutional Ownership by Quarter for Nantkwest (NASDAQ:NK)

Nantkwest (NASDAQ NK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2017Steve GorlinDirectorSell39,604$5.93$234,851.72View SEC Filing  
9/12/2017Steve GorlinDirectorSell103,841$6.04$627,199.64View SEC Filing  
6/20/2017Steve GorlinDirectorSell40,000$7.78$311,200.00View SEC Filing  
11/25/2016John C ThomasDirectorSell6,168$7.50$46,260.00View SEC Filing  
11/23/2016John C ThomasDirectorSell20,000$7.50$150,000.00View SEC Filing  
9/8/2016Barry J SimonInsiderSell32,000$7.49$239,680.00View SEC Filing  
12/10/2015Angela WilsonCFOBuy3,265$15.33$50,052.45View SEC Filing  
8/21/2015Steve GorlinDirectorSell450,000$23.00$10,350,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nantkwest (NASDAQ NK) News Headlines

Source:
DateHeadline
Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders FoundationUpdate in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders Foundation
finance.yahoo.com - December 12 at 10:12 AM
Nantkwests (NK) Hold Rating Reaffirmed at Raymond James FinancialNantkwest's (NK) Hold Rating Reaffirmed at Raymond James Financial
www.americanbankingnews.com - December 11 at 11:50 AM
NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by AnalystsNantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 30 at 5:56 AM
NantKwest, Inc. (NK) Raised to "Buy" at Zacks Investment ResearchNantKwest, Inc. (NK) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 25 at 8:10 PM
NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by BrokeragesNantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 5 at 5:52 AM
NantKwest Becomes OversoldNantKwest Becomes Oversold
www.thestreet.com - November 2 at 6:51 AM
ETFs with exposure to NantKwest, Inc. : October 11, 2017ETFs with exposure to NantKwest, Inc. : October 11, 2017
finance.yahoo.com - October 12 at 7:28 AM
NantKwest, Inc. (NK) Given Consensus Rating of "Hold" by AnalystsNantKwest, Inc. (NK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 11 at 8:49 AM
NantKwest, Inc. (NK) Upgraded by Zacks Investment Research to BuyNantKwest, Inc. (NK) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - October 11 at 6:32 AM
NantKwest (NK) and Its Peers Critical ComparisonNantKwest (NK) and Its Peers Critical Comparison
www.americanbankingnews.com - October 10 at 8:22 PM
NantKwest (NK) Announces Successful First in Human Administration of CD16 haNK Cells - StreetInsider.comNantKwest (NK) Announces Successful First in Human Administration of CD16 haNK Cells - StreetInsider.com
www.streetinsider.com - October 2 at 5:56 PM
ETFs with exposure to NantKwest, Inc. : September 26, 2017ETFs with exposure to NantKwest, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 5:56 PM
NantKwest (NK) Appoints Fred Driscoll to Board - StreetInsider.com - StreetInsider.comNantKwest (NK) Appoints Fred Driscoll to Board - StreetInsider.com - StreetInsider.com
www.streetinsider.com - September 24 at 6:14 AM
NANTKWEST (NK) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary DutyNANTKWEST (NK) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty
finance.yahoo.com - September 22 at 8:52 AM
NANTKWEST INVESTOR INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating NantKwest, Inc. For Potential Breaches of Fiduciary DutyNANTKWEST INVESTOR INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating NantKwest, Inc. For Potential Breaches of Fiduciary Duty
feeds.benzinga.com - September 21 at 7:13 PM
NantKwest, Inc. (NK) Receives Consensus Recommendation of "Hold" from BrokeragesNantKwest, Inc. (NK) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 16 at 6:36 AM
Insider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of StockInsider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of Stock
www.americanbankingnews.com - September 13 at 10:22 PM
NantKwest, Inc. (NK) Director Steve Gorlin Sells 103,841 SharesNantKwest, Inc. (NK) Director Steve Gorlin Sells 103,841 Shares
www.americanbankingnews.com - September 12 at 7:34 PM
ETFs with exposure to NantKwest, Inc. : August 31, 2017ETFs with exposure to NantKwest, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 6:26 AM
NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:15 AM
NantKwest, Inc. (NK) Given Average Rating of "Hold" by BrokeragesNantKwest, Inc. (NK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 22 at 9:08 AM
NantKwest, Inc. – Value Analysis (NASDAQ:NK) : August 15, 2017NantKwest, Inc. – Value Analysis (NASDAQ:NK) : August 15, 2017
finance.yahoo.com - August 15 at 8:32 PM
Here's Why NantKwest Inc. Tumbled 21.1% in JulyHere's Why NantKwest Inc. Tumbled 21.1% in July
finance.yahoo.com - August 10 at 6:10 AM
NantKwest to Present at the 37th Annual Canaccord Genuity Growth ConferenceNantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 7 at 11:41 PM
NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : August 2, 2017NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : August 2, 2017
finance.yahoo.com - August 3 at 6:18 AM
NantKwest (NK) Says Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies Showed Durable Complete ResponsesNantKwest (NK) Says Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies Showed Durable Complete Responses
www.streetinsider.com - July 31 at 10:15 PM
NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological MalignanciesNantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
www.businesswire.com - July 31 at 10:15 PM
NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological MalignanciesNantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
finance.yahoo.com - July 31 at 10:15 PM
Haeggquist & Eck Investigates NantKwest for Misrepresenting ... - Business Wire (press release)Haeggquist & Eck Investigates NantKwest for Misrepresenting ... - Business Wire (press release)
www.businesswire.com - July 27 at 3:25 PM
Haeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary DutyHaeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary Duty
finance.yahoo.com - July 27 at 3:24 PM
NantKwest (NK) Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor AvelumabNantKwest (NK) Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab
www.streetinsider.com - July 27 at 4:47 AM
NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human ...NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human ...
www.businesswire.com - July 27 at 4:47 AM
NantKwest (NK) Announces Publication of Preclinical Data of haNK ... - StreetInsider.comNantKwest (NK) Announces Publication of Preclinical Data of haNK ... - StreetInsider.com
www.streetinsider.com - July 26 at 4:49 AM
NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical TrialsNantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
finance.yahoo.com - July 26 at 4:49 AM
Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors - Business Wire (press release)Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors - Business Wire (press release)
www.businesswire.com - July 16 at 1:27 PM
Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of DirectorsHaeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors
finance.yahoo.com - July 15 at 6:52 AM
Analysts Forecast 10% Upside For The Holdings of IWNAnalysts Forecast 10% Upside For The Holdings of IWN
www.nasdaq.com - July 8 at 1:01 PM
NantKwest, Inc. (NK) Receives Average Rating of "Hold" from AnalystsNantKwest, Inc. (NK) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 3 at 9:15 AM
NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session ... - NasdaqNantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session ... - Nasdaq
www.nasdaq.com - June 17 at 6:03 AM
BRIEF-NantKwest expands nant cancer vaccine programBRIEF-NantKwest expands nant cancer vaccine program
www.reuters.com - June 7 at 11:37 PM
NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 - Business Wire (press release)NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 - Business Wire (press release)
www.businesswire.com - June 3 at 1:17 AM
NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs - Business Wire (press release)NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs - Business Wire (press release)
www.businesswire.com - May 18 at 8:09 AM
NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with ...NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with ...
www.businesswire.com - May 9 at 6:28 PM
NantKwest (NK) and NantCell Announce FDA Authorization for NANT Cancer Vaccine Clinical TrialsNantKwest (NK) and NantCell Announce FDA Authorization for NANT Cancer Vaccine Clinical Trials
www.streetinsider.com - May 9 at 11:32 AM
Court denies NantKwest bid to patent promising cancer treatmentCourt denies NantKwest bid to patent 'promising' cancer treatment
www.reuters.com - May 3 at 10:51 PM
NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
us.rd.yahoo.com - March 21 at 6:43 PM
NantKwest to Present at Upcoming Investor Conferences - Business Wire (press release)NantKwest to Present at Upcoming Investor Conferences - Business Wire (press release)
www.businesswire.com - March 6 at 8:10 AM
Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment ... - Business Wire (press release)Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment ... - Business Wire (press release)
www.businesswire.com - January 24 at 7:49 AM
Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of CancerLandmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
us.rd.yahoo.com - January 23 at 7:09 PM
NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs - Business Wire (press release)NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs - Business Wire (press release)
www.businesswire.com - December 19 at 9:28 AM

SEC Filings

Nantkwest (NASDAQ:NK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nantkwest (NASDAQ:NK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nantkwest (NASDAQ NK) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.